Tri Locum Partners’s Legend Biotech LEGN Stock Holding History

Tri Locum Partners’s Portfolio LEGN Stock Details LEGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-173,260	Closed	-$6.15M	–	24
2025 Q2	$6.15M	Buy	+173,260	New	+$5.61M	1.87%	18
2025 Q1	–	Sell	-388,704	Closed	-$12.6M	–	30
2024 Q4	$12.6M	Buy	388,704 +26,434	+7%	+$1.09M	2.62%	18
2024 Q3	$17.7M	Buy	362,270 +5,738	+2%	+$306K	4.23%	10
2024 Q2	$15.8M	Buy	356,532 +72,759	+26%	+$3.36M	3.99%	15
2024 Q1	$15.9M	Buy	283,773 +181,558	+178%	+$10.9M	5.52%	6
2023 Q4	$6.15M	Buy	+102,215	New	+$6.48M	2.81%	14
2023 Q3	–	Sell	-116,768	Closed	-$8.06M	–	73
2023 Q2	$8.06M	Buy	+116,768	New	+$7.63M	3%	12
2022 Q1	–	Sell	-89,840	Closed	-$4.19M	–	44
2021 Q4	$4.19M	Sell	89,840 -78,627	-47%	-$3.99M	1.65%	18
2021 Q3	$8.52M	Buy	+168,467	New	+$7.01M	3.39%	12

Other funds holding LEGN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Tri Locum Partners's LEGN Position: Q3 2025 in Review

Tri Locum Partners sold out of Legend Biotech (LEGN) in Q3 2025, closing a stake of 173,260 shares — an estimated $6.15M sold.

Tri Locum Partners first reported a position in LEGN in Q3 2021 and held it in 9 quarters. The position peaked at $17.7M in Q3 2024. 199 funds tracked by Wall St. Rank hold LEGN as of Q3 2025.

Tri Locum Partners reported no remaining Legend Biotech position as of Q3 2025 after selling out during the quarter.
Tri Locum Partners sold 173,260 Legend Biotech shares in Q3 2025, an estimated $6.15M.
Tri Locum Partners first reported a position in Legend Biotech in Q3 2021 and held it in 9 quarters.
Tri Locum Partners's Legend Biotech position peaked at $17.7M in Q3 2024.
199 funds tracked by Wall St. Rank held Legend Biotech as of Q3 2025.

Based on Tri Locum Partners's 13F filing for Q3 2025, filed 14 Nov 2025.